



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

17 February 2026  
EMA/13780/2026  
Regulatory Science and Innovation Task Force

## Agenda — Medicine Shortages SPOC Working Party

Tuesday, 17 February 2026, from 09:30 to 13:30 (CET), TEAMS

**Chair: Monica Dias (EMA), Vice-Chair: Vasileios Loutas (PhS, Ministry of Health, Cyprus)**

Item	Topic
1.	Welcome, declaration of interest, adoption of draft agenda
2.	Adoption of draft minutes of the SPOC WP meeting held on 20 January 2026
3.	<b>Potential impact of the international situation</b> on the supply of medicinal products for human and veterinary use to the European market:
	a) Feedback from the SPOC WP subgroup on crisis monitoring and preparedness
	<ul style="list-style-type: none"><li>• Update on the geopolitical situation</li><li>• Availability of antibiotics: update on preparedness activities</li></ul>

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Topic
4.	Oral status update on availability of human and veterinary medicines in MSs (only for new emerging information)
5.	<b>Critical shortages escalated to the SPOC Working Party:</b>
5.1	<b>Ongoing shortages</b>
	a) Medicinal products manufactured by Pharmathen International site
	b) Oncology medicinal products from Teva, Accord
	c) Medicinal products from MAH Cheplapharm <ul style="list-style-type: none"> <li>• Feedback from the SPOC WP Subgroup on Cheplapharm</li> </ul>
	d) Holoxan NAP (ifosfamide), MAH: Baxter
	e) Praziquantel containing medicinal products
	f) Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
5.2	<b>Status update on other critical shortages escalated to the SPOC WP</b> (only comments relating to previously circulated written updates)
	a) NovoSeven CAP (eptacog alfa), MAH: Novo Nordisk
	b) Medicinal products containing salbutamol (inhalation use)
6.	Executive Steering Group on Shortages and Safety of Medicinal Products ( <b>MSSG</b> )-led activities:
	a) Feedback from the MSSG meeting on 30 January 2026 <ul style="list-style-type: none"> <li>• Vulnerability Assessment Methodology — update</li> </ul>
7.	Urban Wastewater Treatment Directive (UWWTD) <ul style="list-style-type: none"> <li>• Potential impact of UWWTD on the supply and availability of medicines</li> </ul>

Item	Topic
8.	EC DG HERA update
9.	SPOC WP <b>F2F March meeting</b> — presentation of draft agenda and call for proposals of agenda topics
10.	AOB
11.	Conclusions and next steps

---

**Next meeting:** 16-17 March 2026, F2F EMA office (Amsterdam) + TEAMS

---